ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efruxifermin

Also written as “Efruxifermin” and “AMG 876”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, Type 2, led by 2 companies.

Drug pageEfruxifermin: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 22, 20236 company-led studies, 3 open or runningAcquisition: Novo Nordisk acquired Akero Therapeutics, Dec 2025Next primary completion: Feb 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only43 open or runningphase 3since Nov 22, 2023Feb 16, 2021Feb 2030phase 3 · NCT06528314
Amgen20 open or runningphase 1since Sep 28, 2011Sep 28, 2011none ahead
  • Named in Novo Nordisk’s own pipeline as Efruxifermin in MASH, phase 3, as of Nov 5, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2011First study: phase 1 study in Diabetes MellitusFirst studyNCT01492465 · 47 enrolled · United States
  2. Mar 25, 2013Phase 1 study in Diabetes MellitusNCT01856881 · 86 enrolled · United States
  3. Jun 7, 2018Akero Therapeutics licensed it from AmgenLicenseWorldwide rights · agreed · Akero Therapeutics (license filed with the SEC)
  4. Dec 19, 2020Named efruxiferminINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AMG 876
  5. Dec 9, 2025Novo Nordisk acquired Akero TherapeuticsAcquisitionWith it the rights Akero held · completed · Novo Nordisk and Akero (release)

TargetBeta

“A long-acting bivalent analog of fibroblast growth factor 21 (FGF21) and fusion protein composed of human immunoglobulin G1 (IgG1) Fc domain attached to a modified form of FGF21, with metabolic regulating, anti-diabetic, and anti-fibrotic activities. Upon administration, efruxifermin mimics FGF21…”NCIt, read by Claude

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
efimosfermin alfaGlaxoSmithKlinephase 310
pegozafermin89bio-incphase 38
zalferminNovo Nordiskphase 210

Studies

All 2 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01856881Diabetes Mellitus · United States1TerminatedNov 201486
NCT01492465Diabetes Mellitus · United States1TerminatedJul 201247

How it is read

Names in the registry

  • “Efruxifermin”, 4 entries
  • “AMG 876”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.